146 related articles for article (PubMed ID: 9527797)
1. In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.
MacGowan AP; Bowker KE; Wootton M; Holt HA; Reeves DS
Antimicrob Agents Chemother; 1998 Feb; 42(2):419-24. PubMed ID: 9527797
[TBL] [Abstract][Full Text] [Related]
2. The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.
Bowker KE; Wootton M; Holt HA; Reeves DS; MacGowan AP
J Antimicrob Chemother; 1996 Aug; 38(2):271-81. PubMed ID: 8877542
[TBL] [Abstract][Full Text] [Related]
3. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
4. A review of the antimicrobial activity of the fluoroquinolones.
Maple P; Brumfitt W; Hamilton-Miller JM
J Chemother; 1990 Oct; 2(5):280-94. PubMed ID: 2128638
[TBL] [Abstract][Full Text] [Related]
5. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria.
MacGowan AP; Bowker KE; Holt HA; Wootton M; Reeves DS
J Antimicrob Chemother; 1997 Oct; 40(4):503-9. PubMed ID: 9372419
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin.
Mirelis B; Navarro F; Miró E; Coll R; Xicota MA; Prats G
Drugs Exp Clin Res; 1995; 21(4):129-38. PubMed ID: 8529525
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of gatifloxacin, a new fluoroquinolone, against 204 anaerobes compared to seven other compounds.
Dubreuil L; Behra-Miellet J; Neut C; Calvet L
Clin Microbiol Infect; 2003 Nov; 9(11):1133-8. PubMed ID: 14616733
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects.
Gootz TD; Brighty KE
Med Res Rev; 1996 Sep; 16(5):433-86. PubMed ID: 8865150
[No Abstract] [Full Text] [Related]
10. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.
Clement JJ; Tanaka SK; Alder J; Vojtko C; Beyer J; Hensey D; Ramer N; McDaniel D; Chu DT
Antimicrob Agents Chemother; 1994 May; 38(5):1071-8. PubMed ID: 8067740
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.
Wexler HM; Molitoris E; Molitoris D; Finegold SM
Antimicrob Agents Chemother; 1996 Sep; 40(9):2232-5. PubMed ID: 8878617
[TBL] [Abstract][Full Text] [Related]
12. E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.
Guinea J; Gargallo-Viola D; Robert M; Tudela E; Xicota MA; Garcia J; Esteve M; Coll R; Pares M; Roser R
Antimicrob Agents Chemother; 1995 Feb; 39(2):413-21. PubMed ID: 7726507
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of three of the newer quinolones against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1992 Jan; 36(1):239-43. PubMed ID: 1317149
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes.
Biedenbach DJ; Jones RN
Antimicrob Agents Chemother; 1995 Jul; 39(7):1636-42. PubMed ID: 7492122
[TBL] [Abstract][Full Text] [Related]
15. In vitro antibacterial activity of the new quinolone Bay y3118 against clinical isolates.
Ravizzola G; Pizzi R; Pirali F; Turano A
J Chemother; 1994 Dec; 6(6):392-8. PubMed ID: 7699426
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
Nord CE; Lindmark A; Persson I
Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
[TBL] [Abstract][Full Text] [Related]
17. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Haas W; Pillar CM; Zurenko GE; Lee JC; Brunner LS; Morris TW
Antimicrob Agents Chemother; 2009 Aug; 53(8):3552-60. PubMed ID: 19506065
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
Hu J; Zhang J; Wu S; Zhu D; Huang H; Chen Y; Yang Y; Zhang Y
Int J Antimicrob Agents; 2014 Dec; 44(6):514-9. PubMed ID: 25301712
[TBL] [Abstract][Full Text] [Related]
19. Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria.
Genzel GH; Stubbings W; Stîngu CS; Labischinski H; Schaumann R
Int J Antimicrob Agents; 2014 Nov; 44(5):420-3. PubMed ID: 25264128
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
Moros M; Coll R; Esteve M; Parés J; Xicota MA
Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
[No Abstract] [Full Text] [Related]
[Next] [New Search]
